RecruitingNCT06898320
Cardiac Injury Due to Anthracycline in Paediatric Oncological Patients
Prediction of Cardiac Injury Due to Anthracycline Chemotherapy in Paediatric Oncological Patients Using Advanced Echocardiography and Circulating Biomarkers.
Sponsor
IRCCS Burlo Garofolo
Enrollment
22 participants
Start Date
Jul 21, 2023
Study Type
OBSERVATIONAL
Conditions
Summary
The study investigates the role of echocardiography and of serum biomarkers (NT-proBNP, cardiac Troponin-I) in predicting cardiac injury in a cohort of paediatric oncological patients treated with Anthracycline chemotherapy.
Eligibility
Min Age: 0 YearsMax Age: 18 Years
Inclusion Criteria3
- Paediatric oncological patients 0-18 years
- Planned start of anthracycline therapy
- Normal left ventricular systolic function according to International Guidelines before the treatment with AC
Exclusion Criteria5
- Previous anthracycline treatment, bone marrow transplantation or chest radiation
- Pre-anthracycline treatment echocardiographic evidence of:
- More than mild pericardial effusion
- More than mild mitral regurgitation
- Poor echocardiographic acoustic window
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06898320